- Home
- SOPA vs MYNZ Comparison
SOPA vs MYNZ Comparison
Compare SOPA & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPA
- MYNZ
- Stock Information
- Founded
- SOPA 2018
- MYNZ 2021
- Country
- SOPA Singapore
- MYNZ Germany
- Employees
- SOPA N/A
- MYNZ N/A
- Industry
- SOPA EDP Services
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- SOPA Technology
- MYNZ Health Care
- Exchange
- SOPA Nasdaq
- MYNZ Nasdaq
- Market Cap
- SOPA 7.3M
- MYNZ 7.9M
- IPO Year
- SOPA 2021
- MYNZ 2021
- Fundamental
- Price
- SOPA $4.12
- MYNZ $1.60
- Analyst Decision
- SOPA Strong Buy
- MYNZ Buy
- Analyst Count
- SOPA 1
- MYNZ 2
- Target Price
- SOPA $18.00
- MYNZ $14.00
- AVG Volume (30 Days)
- SOPA 11.2M
- MYNZ 387.7K
- Earning Date
- SOPA 11-14-2025
- MYNZ 09-26-2025
- Dividend Yield
- SOPA N/A
- MYNZ N/A
- EPS Growth
- SOPA N/A
- MYNZ N/A
- EPS
- SOPA N/A
- MYNZ N/A
- Revenue
- SOPA $7,522,939.00
- MYNZ $659,935.00
- Revenue This Year
- SOPA N/A
- MYNZ $26.06
- Revenue Next Year
- SOPA $45.16
- MYNZ $4.97
- P/E Ratio
- SOPA N/A
- MYNZ N/A
- Revenue Growth
- SOPA 0.31
- MYNZ N/A
- 52 Week Low
- SOPA $0.64
- MYNZ $1.28
- 52 Week High
- SOPA $6.75
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- SOPA 81.66
- MYNZ 35.56
- Support Level
- SOPA $1.11
- MYNZ $1.55
- Resistance Level
- SOPA $6.28
- MYNZ $1.73
- Average True Range (ATR)
- SOPA 0.45
- MYNZ 0.12
- MACD
- SOPA 0.43
- MYNZ -0.01
- Stochastic Oscillator
- SOPA 69.69
- MYNZ 5.56
About SOPA Society Pass Incorporated
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.